| That's right. At least different analyst targets are suggesting OKYO to have triple-digit upside potential from Thursday's closing valuation.
More specifically:
Lucid Capital Markets' $13 target suggests over 350% potential upside.
Goldman Small Cap Research's $8 target suggests more than 175% potential upside
And H.C. Wainwright & Co.'s $7 target suggests 150+% potential upside.
Take a moment to click the picture above and get a look at all 3 reports. -----
No. 2 OKYO Potential Catalyst - A Multitude Of Bullish Technical Indicators Surround OKYO Across 3 Separate Terms.
On Thursday at 4:00PM EST, Barchart was reporting several triggered technical indicators indicators across the short, medium, and long term for OKYO.
Here's their list (as of 4:00PM EST Thursday):
Short Term Indicators
- 20 - 50 Day MA Crossover
- 20 - 100 Day MA Crossover
- 20 - 200 Day MA Crossover
Medium Term Indicators
- 50 Day Moving Average
- 50 - 100 Day MA Crossover
- 50 - 150 Day MA Crossover
- 50 - 200 Day MA Crossover
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
- 100 - Day MA Crossover
Make sure to watch these technical indicators closely moving forward. -----
No. 3 OKYO Potential Catalyst - Positive Top-Line Data Announced From Phase 2 Clinical Trial Results For Urcosimod.
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
- After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.
- Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.
- A statistically significant reduction in mean pain scores was observed from Visit 1 to the end of treatment Visit 4 (p-value = 0.025) in the per-protocol 0.05% urcosimod group, indicating the drug’s effectiveness over the study period.
- Notably, all these responders entered the study with moderate to severe NCP pain scores despite prior use of maximum medical therapy.
- No serious adverse events were reported among the 18 patients throughout the trial.
- Following completion of full data analysis, OKYO plans a meeting with FDA to discuss next steps for urcosimod which has already received Fast Track designation for treating NCP.
LONDON and NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), ..., is pleased to announce positive top-line data from the recently closed 18-patient Phase 2 trial of urcosimod (formerly called OK-101) to treat NCP. OKYO is the first company to conduct a clinical study to treat NCP disease, a major unmet medical need.
...
“We are thrilled with these initial top-line results in patients treated with urcosimod from this first in-human phase 2 trial,” said Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma. “In particular, the results strengthen our conviction that this drug may be particularly effective at showing a significant reduction in pain in patients with a greater degree of neuropathic pain. Throughout the trial we were also pleased by the feedback from patients and are excited about the opportunity to provide relief to NCP patients currently living day-to-day with the life-altering effects of this relentless neuropathic pain. I want to thank Dr. Pedram Hamrah, one of the world’s foremost experts on NCP, and our patients and study site team for their participation and commitment to this important trial of urcosimod to treat NCP.”
“I am very proud that OKYO Pharma is pioneering the development of the first topical drug with the potential to treat Neuropathic Corneal Pain, a debilitating disease, which currently has no FDA approved therapy,’’ said Mr. Gabriele Cerrone, Founder and Chairman of OKYO Pharma. “Our goal now is to bring this drug to the market as quickly as possible to help patients suffering from this terrible disease.”
...
Read the full article here. -----
No. 4 OKYO Potential Catalyst - A New Milestone For The Company Is Reached With FDA Granted Fast Track Designation To Urcosimod.
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP).
Fast Track designation by the FDA is granted to facilitate the development and expedite the review of therapies that aim to treat serious conditions and fulfill unmet medical needs. This designation is intended to accelerate the availability of new treatments to patients, providing earlier access to potentially beneficial therapies. The Fast Track designation provides several key benefits, including more frequent meetings with the FDA to discuss the drug’s development plan, eligibility for Accelerated Approval and Priority Review if relevant criteria are met, and a potential Rolling Review of the New Drug Application (NDA).
...
Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, expressed his enthusiasm about the FDA's decision: "We are thrilled with the FDA's Fast Track designation for urcosimod in the treatment of neuropathic corneal pain. This milestone underscores our commitment to advancing innovative therapies that can make a meaningful difference in patients' lives. We look forward to working closely with the FDA to bring this promising treatment to patients as quickly as possible."
...
Read the full article here. -----
No. 5 OKYO Potential Catalyst - With A Relatively Low Float, Volatility Potential Could Be Heightened (Daily).
According to info from the Yahoo website, OKYO has a relatively low float.
The website reports this profile to have roughly 25.08Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears in the midway part of 2025, could this low float potential help create a spark? -----
(Nasdaq: OKYO) Recap - 5 Potential Breakout Catalysts Lead The Way!
No. 1 - At Least 3 Analyst Targets Are Suggesting OKYO To Have Triple-Digit Upside Potential!
No. 2 - A Multitude Of Bullish Technical Indicators Surround OKYO Across 3 Separate Terms.
No. 3 - Positive Top-Line Data Announced From Phase 2 Clinical Trial Results For Urcosimod.
No. 4 - A New Milestone For The Company Is Reached With FDA Granted Fast Track Designation To Urcosimod.
No. 5 - With A Relatively Low Float, Volatility Potential Could Be Heightened (Daily). -----
Coverage is now officially underway on OKYO Pharma Limited (Nasdaq: OKYO).
Be ready for updates coming soon.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 08/01/2025 and ending on 08/01/2025 to publicly disseminate information about (OKYO:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (OKYO:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/okyo-sxsk6/#details | 
No comments:
Post a Comment